Biodesix, located in Boulder CO, is developing a way to predict whether a melanoma patient is likely to benefit from high dose interleukin-2 (IL2) therapy in treatment of cancer. It uses mass spectrometry data obtained from a blood-based sample of the patient and uses classifiers to guide treatment of the melanoma patient.